<!DOCTYPE html SYSTEM "about:legacy-compat">
<html lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>.03 Definitions. | Library of Maryland Regulations</title>
    <link rel="shortcut icon" href="/us/md/exec/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="full-html" content="/us/md/exec/comar/10.10/index.full.html" data-document="href"/>
    <meta itemprop="toc-json" content="/us/md/exec/comar/10.10/index.json" data-document="href"/>
    <meta itemprop="parent-doc-url" content="/us/md/exec/comar" data-document="href"/>
    <meta itemprop="order" content="|10|10|13|.03|"/>
    <meta itemprop="doc-type" content="section" data-document=""/>
    <meta itemprop="ref-doc" content="Code of Maryland Regulations" data-document=""/>
    <meta itemprop="ref-path" content="10|10|13|.03" data-document=""/>
    <!--OpenGraph-->
    <meta property="og:url" content="/us/md/exec/comar/10.10.13.03"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content=".03 Definitions. | Library of Maryland Regulations"/>
    <meta property="og:image" content="/us/md/exec/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#0078EF"/>
    <meta name="apple-mobile-web-app-title" content="Library of Maryland Regulations"/>
    <meta name="theme-color" content="#0078EF"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/md/exec/_document/v2/images/favicons/safari-pinned-tab.svg" color="#0078EF"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/md/exec/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/md/exec/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/md/exec/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/md/exec/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/public-sans/public-sans.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/merriweather/merriweather.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/roboto-mono/roboto-mono.css" type="text/css" rel="stylesheet" data-document=""/>
    <!--Document CSS-->
    <link href="/us/md/exec/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print" data-document=""/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js" data-document=""> </script>
    <!--Links to resources that need to be prefetched-->
    <link rel="prefetch" href="/us/md/exec/comar/10.10/index.full.html" as="fetch"/>
    <link rel="prefetch" href="/index.json" as="fetch"/>
    <link rel="prefetch" href="/us/md/exec/comar/10.10/index.json" as="fetch"/>
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__maryland-dsd">
      <header id="section__header" class="ns__document__maryland-dsd">
        <div id="section__header__inner" class="ns__document__maryland-dsd">
          <div id="area__logo" class="ns__document__maryland-dsd">
            <a href="/" class="logo" aria-label="Logo - Return to library home page">
              <img src="/us/md/exec/_document/v2/images/logo/logo.png" srcset="/us/md/exec/_document/v2/images/logo/logo.png 1x, /us/md/exec/_document/v2/images/logo/logo@2x.png 2x, /us/md/exec/_document/v2/images/logo/logo@3x.png 3x" alt="Library of Maryland Regulations logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__maryland-dsd">
            <div class="h__library-logotype"><span class="line1">Library of</span> <span class="line2">Maryland Regulations</span></div>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__maryland-dsd">
        <div id="section__content__inner" class="ns__document__maryland-dsd">
          <section id="area__breadcrumbs" class="ns__document__maryland-dsd" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="Library of Maryland Regulations">Library of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations" data-search-heading="" data-search-default="true" class="li__book-open">
                  <a href="/us/md/exec/comar" title="Code of Maryland Regulations">Code of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10" data-search-heading="">
                  <a href="/us/md/exec/comar/10" title="Title 10 MARYLAND DEPARTMENT OF HEALTH">Title 10 MARYLAND DEPARTMENT OF HEALTH</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|10" data-search-heading="">
                  <a href="/us/md/exec/comar/10.10" title="Subtitle 10 LABORATORIES">Subtitle 10 LABORATORIES</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|10|13" data-search-heading="">
                  <a href="/us/md/exec/comar/10.10.13" title="Chapter 13 Medical Laboratories — Testing for Hereditary and Congenital Disorders in Newborn Infants">Chapter 13 Medical Laboratories — Testing for Hereditary and Congenital Disorders in Newborn Infants</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|10|13|.03" data-search-heading="">
                  <span title=".03 Definitions.">.03 Definitions.</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__maryland-dsd">
            <div class="h__document-title">Code of Maryland Regulations</div>
            <article class="content" role="document" data-ref-path="10|10|13|.03">
              <div class="tuf-authenticate">
                <h1 class="h__toc" id="/us/md/exec/comar/10.10.13.03">.03 Definitions.</h1>
                <p class="text-indent-1 "><span class="level-num" id="A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(1)">(1)</span> "Abnormal test result" means a first-tier, supplemental, or second-tier test result that:</p>
                <p class="text-indent-3 "><span class="level-num" id="B(1)(a)">(a)</span> Falls outside the normal range for the analyte measured; and</p>
                <p class="text-indent-3 "><span class="level-num" id="B(1)(b)">(b)</span> Triggers a request for additional testing or is diagnostic for a disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(2)">(2)</span> Allele.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(2)(a)">(a)</span> "Allele" means any one of a series of two or more different forms of a gene or DNA sequence that can exist at a single locus on a chromosome.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(2)(b)">(b)</span> "Allele" includes the gene or DNA sequence for hemoglobin traits and disease states, such as hemoglobin S (HbS) for sickle cell disease.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(3)">(3)</span> "Analyte" means the substance or chemical constituent in blood being measured in a screening test used to detect the disorders listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(4)">(4)</span> Birthing Facility.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(4)(a)">(a)</span> "Birthing facility" means a facility that provides the antepartum, intrapartum, and postpartum management and care of women and their newborn infants.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(4)(b)">(b)</span> "Birthing facility" includes a:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(4)(b)(i)">(i)</span> Birthing service that is licensed or accredited as a unit of a hospital; and</p>
                <p class="text-indent-4 "><span class="level-num" id="B(4)(b)(ii)">(ii)</span> Freestanding birthing center as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.05.02.01#B" title="">COMAR 10.05.02.01B</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(5)">(5)</span> Blood-Spot Specimen.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(5)(a)">(a)</span> “Blood-spot specimen” means a whole-blood specimen collected from a newborn infant’s heel and applied to the designated area on a blood-spot collection test requisition card for the purpose of performing screening tests.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(5)(b)">(b)</span> “Blood-spot specimen” includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(5)(b)(i)">(i)</span> The first screening blood-spot specimen collected from a newborn infant, usually in the birthing facility or other place where the newborn infant was born, within 48 hours after the newborn infant’s birth;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(5)(b)(ii)">(ii)</span> The second screening blood-spot specimen collected from a newborn infant, usually collected when the newborn infant is between 10 and 14 days of age; and</p>
                <p class="text-indent-4 "><span class="level-num" id="B(5)(b)(iii)">(iii)</span> A blood-spot specimen collected subsequent to a blood-spot specimen specified in §B(5)(b)(i) and (ii) of this regulation as required to meet the medical needs and condition of the newborn infant and any additional specific screening blood-spot specimen collection and screening test requirements of this chapter and <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12" title="Chapter 12 Newborn Screening">COMAR 10.52.12</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(6)">(6)</span> "Borderline result" means a screening test result that is at or near the established cut-off level for a particular analyte.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(7)">(7)</span> "CLIA" means the federal Clinical Laboratory Improvement Amendments of 1988.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(8)">(8)</span> Congenital Disorder.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(8)(a)">(a)</span> "Congenital disorder" means a significant structural or functional abnormality of the body that is present at birth.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(8)(b)">(b)</span> "Congenital disorder" does not include a condition that results from:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(8)(b)(i)">(i)</span> An intrauterine infection; or</p>
                <p class="text-indent-4 "><span class="level-num" id="B(8)(b)(ii)">(ii)</span> A birth injury.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(9)">(9)</span> "Council" means the State Advisory Council on Hereditary and Congenital Disorders.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(10)">(10)</span> “Courier” means an entity employed by a person to convey a blood-spot specimen from the site of blood-spot specimen collection to the laboratory where the blood-spot specimen will be tested.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(11)">(11)</span> "Cut-off level" means a pre-determined, measurable value established for an analyte detected by a screening test, where that value is used to determine when a newborn infant's test result is normal, borderline, or abnormal.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(12)">(12)</span> "Department" means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(13)">(13)</span> "Diagnostic test" means a test that is used to establish or confirm the presence of a:</p>
                <p class="text-indent-3 "><span class="level-num" id="B(13)(a)">(a)</span> Specific disease; or</p>
                <p class="text-indent-3 "><span class="level-num" id="B(13)(b)">(b)</span> Hereditary or congenital disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(14)">(14)</span> “First screening” means a screening performed on the first blood-spot specimen collected from a newborn infant after birth.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(15)">(15)</span> “First–tier test” means a blood test performed on a newborn infant’s blood-spot specimen that:</p>
                <p class="text-indent-3 "><span class="level-num" id="B(15)(a)">(a)</span> Indicates the probable presence or absence of a hereditary or congenital disorder; or</p>
                <p class="text-indent-3 "><span class="level-num" id="B(15)(b)">(b)</span> Identifies a newborn infant who is at increased risk for a hereditary or congenital disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(16)">(16)</span> “Follow-Up Unit” means the follow-up component and staff of the Department’s Newborn Screening Program, which carries out the duties set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12.12" title=".12 Follow-Up Procedures.">COMAR 10.52.12.12</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(17)">(17)</span> Hereditary Disorder.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(17)(a)">(a)</span> "Hereditary disorder" means a disorder that:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(17)(a)(i)">(i)</span> Is transmissible through the genetic material deoxyribonucleic acid (DNA); or</p>
                <p class="text-indent-4 "><span class="level-num" id="B(17)(a)(ii)">(ii)</span> Arises through the improper processing of information in the genetic material.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(17)(b)">(b)</span> "Hereditary disorder" includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(17)(b)(i)">(i)</span> Hemoglobin disorders;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(17)(b)(ii)">(ii)</span> Metabolic disorders; and</p>
                <p class="text-indent-4 "><span class="level-num" id="B(17)(b)(iii)">(iii)</span> Endocrine disorders.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(18)">(18)</span> “Home birth” means the birth of an infant which occurs intentionally outside of a birthing facility.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(19)">(19)</span> “Home birth attendant” means a physician who is licensed to practice under <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gho/gho.pdf" title="">Health Occupations Article, Title 14, Annotated Code of Maryland</a>, a nurse midwife who is licensed and certified under <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gho/gho.pdf" title="">Health Occupations Article, Title 8, Annotated Code of Maryland</a>, or a direct-entry midwife who is licensed under <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gho/gho.pdf" title="">Health Occupations Article, Title 8, Subtitle 6C, Annotated Code of Maryland</a>, who is caring for the mother and infant at delivery during a home birth as defined in <a class="internal-link " href="/us/md/exec/comar/10.10.13.03#B(18)" title="">§B(18) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(20)">(20)</span> "Metabolic Disorder" means a disorder caused by a genetic alteration that results in a defect in the function of a specific enzyme, hormone, or protein, which can be detected by:</p>
                <p class="text-indent-3 "><span class="level-num" id="B(20)(a)">(a)</span> Direct analysis of the enzyme, hormone, or protein; or</p>
                <p class="text-indent-3 "><span class="level-num" id="B(20)(b)">(b)</span> Testing for a substance whose metabolism is altered as a result of the defect.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(21)">(21)</span> "Newborn" or "newborn infant" means an infant:</p>
                <p class="text-indent-3 "><span class="level-num" id="B(21)(a)">(a)</span> Born in Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(21)(b)">(b)</span> Born on federal property within Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(21)(c)">(c)</span> Born outside of Maryland to parents whose residence is in Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(21)(d)">(d)</span> From whom a blood-spot specimen was collected and submitted to the Department’s public health laboratory for newborn screening by a birthing facility or other health care provider located in Maryland, regardless of the infant’s place of birth;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(21)(e)">(e)</span> Who has a screening test requested by the Follow-Up Unit:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(21)(e)(i)">(i)</span> For first-tier screening follow-up;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(21)(e)(ii)">(ii)</span> For confirmation of a previous screening test result; or</p>
                <p class="text-indent-4 "><span class="level-num" id="B(21)(e)(iii)">(iii)</span> To assist with a newborn infant's diagnosis, therapy, or follow-up care; or</p>
                <p class="text-indent-3 "><span class="level-num" id="B(21)(f)">(f)</span> Who is in Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(22)">(22)</span> Newborn Screening or Screening.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(22)(a)">(a)</span> "Newborn screening" or "screening" means one or more first-tier tests.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(22)(b)">(b)</span> "Newborn screening" or "screening" includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(22)(b)(i)">(i)</span> First-tier testing on a first, second, or subsequent blood-spot specimen; and</p>
                <p class="text-indent-4 "><span class="level-num" id="B(22)(b)(ii)">(ii)</span> Supplemental first-tier testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(23)">(23)</span> Newborn Screening Program.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(23)(a)">(a)</span> "Newborn Screening Program" means the Department's screening program for hereditary and congenital disorders, which performs operations and activities necessary to ensure that:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(23)(a)(i)">(i)</span> Newborn infants are given the opportunity to be tested;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(23)(a)(ii)">(ii)</span> At risk newborn infants who are tested are identified and located;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(23)(a)(iii)">(iii)</span> Newborn infants are given access to necessary follow-up testing;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(23)(a)(iv)">(iv)</span> Diagnostic tests are available and the diagnosis is made or ruled out; and</p>
                <p class="text-indent-4 "><span class="level-num" id="B(23)(a)(v)">(v)</span> Newborn infants diagnosed with a hereditary or congenital disorder are given access to treatment.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(23)(b)">(b)</span> "Newborn Screening Program" includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(23)(b)(i)">(i)</span> The Department's public health laboratory as the sole screening laboratory;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(23)(b)(ii)">(ii)</span> Another state's public health laboratory or a commercial laboratory that may serve the State as a screening laboratory during an emergency under a Departmental mutual aid agreement;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(23)(b)(iii)">(iii)</span> Supplemental and second-tier testing performed by a state public health laboratory or by a permitted commercial or research laboratory;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(23)(b)(iv)">(iv)</span> The Follow-Up Unit; and</p>
                <p class="text-indent-4 "><span class="level-num" id="B(23)(b)(v)">(v)</span> The State Advisory Council on Hereditary and Congenital Disorders.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(24)">(24)</span> "Normal limit" means a measurable, numerical value or range that is considered not to indicate or establish the presence of a hereditary or congenital disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(25)">(25)</span> "Permittee" means a person issued a permit by the Secretary to operate a medical laboratory as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(26)">(26)</span> "Public health laboratory" means:</p>
                <p class="text-indent-3 "><span class="level-num" id="B(26)(a)">(a)</span> The Department's public health laboratory; and</p>
                <p class="text-indent-3 "><span class="level-num" id="B(26)(b)">(b)</span> Another state's public health laboratory or a commercial laboratory permitted in Maryland that is approved under a Departmental emergency mutual aid agreement to perform newborn screening tests on Maryland newborns.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(27)">(27)</span> Quality Assessment Plan.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(27)(a)">(a)</span> "Quality assessment plan" means a planned system of step-by-step activities to ensure that:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(27)(a)(i)">(i)</span> Testing is carried out according to the manufacturer's instructions;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(27)(a)(ii)">(ii)</span> Testing results are accurate and reliable;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(27)(a)(iii)">(iii)</span> Testing problems and errors are found and corrected to avoid adverse health outcomes for newborn infants; and</p>
                <p class="text-indent-4 "><span class="level-num" id="B(27)(a)(iv)">(iv)</span> Testing results are reported and communicated in a timely manner as required by this chapter.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(27)(b)">(b)</span> "Quality assessment plan" includes the ongoing activities that monitor, review, evaluate, and improve the overall quality of the procedures and processes before, during, and after a test is performed.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(28)">(28)</span> "Quality control" has the meaning stated in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.03#B" title="">COMAR 10.10.06.03B</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(29)">(29)</span> Screening Test.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(29)(a)">(a)</span> "Screening test" means a first-tier test used to detect a hereditary or congenital disorder listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12" title=".12 First-Tier, Supplemental, and Second-Tier Tests.">Regulation .12 of this chapter</a>.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(29)(b)">(b)</span> “Screening test” includes a test performed on a:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(29)(b)(i)">(i)</span> First screening blood-spot specimen;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(29)(b)(ii)">(ii)</span> Second screening blood-spot specimen; or</p>
                <p class="text-indent-4 "><span class="level-num" id="B(29)(b)(iii)">(iii)</span> Subsequent screening blood-spot specimen.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(29)(c)">(c)</span> "Screening test" does not include a:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(29)(c)(i)">(i)</span> Diagnostic test; or</p>
                <p class="text-indent-4 "><span class="level-num" id="B(29)(c)(ii)">(ii)</span> Second-tier test.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(30)">(30)</span> “Second screening” means a test performed on a routine second blood-spot specimen collected when the newborn infant is between 10 and 14 days old even though the test results from the newborn’s first blood-spot specimen were normal.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(31)">(31)</span> Second-Tier Test.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(31)(a)">(a)</span> “Second-tier test” means a test performed on a newborn screening blood-spot specimen when a first-tier test provides an abnormal screening test result or a borderline abnormal screening test result.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(31)(b)">(b)</span> "Second-tier test" includes a test that:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(31)(b)(i)">(i)</span> Establishes or confirms a newborn infant's risk for a hereditary or congenital disorder;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(31)(b)(ii)">(ii)</span> Separates a newborn infant into a lower or higher risk category for a hereditary or congenital disorder; or</p>
                <p class="text-indent-4 "><span class="level-num" id="B(31)(b)(iii)">(iii)</span> Is diagnostic because it confirms the presence of a hereditary or congenital disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(32)">(32)</span> "Secretary" means the Secretary of Health or the Secretary's designee.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(33)">(33)</span> “Supplemental test” means a test performed on a blood-spot specimen collected from a newborn infant that is:</p>
                <p class="text-indent-3 "><span class="level-num" id="B(33)(a)">(a)</span> Used to detect a hereditary or congenital disorder not specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C of this chapter</a>; or</p>
                <p class="text-indent-3 "><span class="level-num" id="B(33)(b)">(b)</span> Not required to be performed by the Department's public health laboratory under this chapter or <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12" title="Chapter 12 Newborn Screening">COMAR 10.52.12</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(34)">(34)</span> “Unsatisfactory blood-spot specimen” means a blood-spot specimen that may produce an inaccurate or unreliable test result because the blood-spot specimen exhibits one of the problems of collection as specified in Regulation .21B and C of this chapter.</p>
              </div>
            </article>
          </main>
          <nav id="area__navigation_mini" class="ns__document__maryland-dsd" aria-label="Previous and next article links">
            <section>
              <a href="/us/md/exec/comar/10.10.13.02" aria-label=".02 Scope.">
                <div class="h__ui">Previous</div>
                <span>.02 Scope.</span>
              </a>
            </section>
            <section>
              <a href="/us/md/exec/comar/10.10.13.04" aria-label=".04 Permit.">
                <div class="h__ui">Next</div>
                <span>.04 Permit.</span>
              </a>
            </section>
          </nav>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__maryland-dsd">
        <div id="section__footer__inner" class="ns__document__maryland-dsd">
          <div id="area__footer__content" class="ns__document__maryland-dsd">
            <p>The codes and laws on this website are in the public domain.</p>
            <p>
      Please do not scrape. Instead, bulk download the <a href="https://github.com/maryland-dsd/law-html">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml">XML</a>.
    </p>
            <p>Powered by the non-profit <a href="http://www.openlawlib.org/">Open Law Library</a>.</p>
          </div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
